Crossmark

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study

Crossref DOI link: https://doi.org/10.1007/s10549-025-07656-z

Published Online: 2025-03-06

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

McCann, Kelly E. https://orcid.org/0000-0001-8233-6242
Osman, Noran https://orcid.org/0009-0000-5630-874X
Cannon, Joan https://orcid.org/0009-0009-2410-7295
Brent, Lonnie

Wang, Yuexi https://orcid.org/0009-0000-9455-5143
Tepsick, Jon https://orcid.org/0000-0001-6035-7800
Mandora, Prithviraj Vikramsinh

Miller, Vincent https://orcid.org/0009-0006-0618-1211
Martin, Nancy https://orcid.org/0009-0008-5706-4829
Kaklamani, Virginia G. https://orcid.org/0000-0002-3313-8458
Funding

Funding for this research was provided by:

TerSera Therapeutics LLC
License Information

Text and Data Mining valid from 2025-03-06

Version of Record valid from 2025-03-06
More Information

Article History

Received: 2 December 2024

Accepted: 15 February 2025

First Online: 6 March 2025

Declarations

:

: KEM reports being on a speaker’s bureau for Eli Lilly; being on advisory boards for Arvinas, AstraZeneca, Biotheranostics, Eli Lilly, Novartis, and Stemline Therapeutics; and being a consultant for AstraZeneca, Biovica International AB, Eli Lilly, Novartis, Puma Biotechnology, and TerSera Therapeutics. NO, JC, and LB are employed by TerSera Therapeutics. YW, JT, PVM, and VM report research funding to their institution from TerSera Therapeutics. NM was employed by TerSera Therapeutics during the conduct of this research. VGK reports being a speaker and consultant for AstraZeneca, Daiichi Sankyo, and Gilead; being a consultant for Eli Lilly, Genentech, Menarini, Puma Biotechnology, and TerSera Therapeutics; and receiving research funding from Eisai.

: This research was reviewed and determined to be exempt from Institutional Review Board (IRB) oversight by Advarra IRB (Columbia, Maryland). This research study was conducted retrospectively from data obtained for clinical purposes. The data used in this study were all collected originally for clinical use in the practice setting and are therefore considered secondary data. Only de-identified data were utilized in the analysis, and unique patient identifiers were completely removed from the analytical dataset.

: Informed consent was not applicable for the research described in this article.

: Part of this research was presented at the San Antonio Breast Cancer Symposium (SABCS) (December 10-13, 2024).

Document is current

Any future updates will be listed below